Details for New Drug Application (NDA): 020228
✉ Email this page to a colleague
NDA 020228 describes ATROVENT, which is a drug marketed by Boehringer Ingelheim and is included in five NDAs. There is one patent protecting this drug. Additional details are available on the ATROVENT profile page.
The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
Summary for 020228
| Tradename: | ATROVENT |
| Applicant: | Boehringer Ingelheim |
| Ingredient: | ipratropium bromide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020228
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INHALATION | Strength | 0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 29, 1993 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
